Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Daklinza

- PMLiVE

BMS pays Zenas $50m upfront for regional rights to autoimmune disease antibody

The company will gain exclusive rights to develop and commercialise obexelimab

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

- PMLiVE

BMS launches campaign to highlight impact of psoriasis on patient well-being

An estimated 7.5 million people in the US are affected by some form of the condition

- PMLiVE

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

The long-term inflammatory skin condition affects an estimated 1% of the global population

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by CHMP for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

BMS obtains global rights to Prothena’s Alzheimer’s drug in deal worth $2.2bn

The decision comes two years after the company paid $80m for opt-in rights to PRX005

- PMLiVE

Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

- PMLiVE

AbbVie files patent infringement lawsuit against BeiGene’s blood cancer drug Brukinsa

The BTK inhibitor was approved in the US earlier this year and had its patent issued last week

- PMLiVE

AbbVie announces positive phase 3 results for Skyrizi in ulcerative colitis

Inflammatory bowel disease is estimated to affect nearly one in every 100 people in the US

- PMLiVE

BMS presents positive four-year results for Opdivo combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links